NCT00107913

Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura

Phase II Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 10 (planned)
• Sponsor: Hematology and Oncology Specialists · Academic / Other
• Sex: All
• Age: 0 Years
• Healthy volunteers: Not accepted

Summary

This study is designed to evaluate the efficacy and safety of single agent Doxil in the treatment of patients with refractory ITP (Idiopathic Thrombocytopenic Purpura).

Detailed description

Eligible patients will receive Doxil 20 mg/m2 IV over 1 hour every 2 weeks. Treatment will be continued for 1 course beyond return of the platelet count to normal with a maximum of 18 courses.

Conditions

• Autoimmune Thrombocytopenic Purpura

Interventions

Type	Name	Description
DRUG	Doxil

Timeline

• Start date: 2001-09-01
• Completion: 2005-04-01
• First posted: 2005-04-12
• Last updated: 2005-06-24

Locations

1 site across 1 country: United States